ALKEM LABORATORIES | SUN PHARMA | ALKEM LABORATORIES/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 21.2 | 34.1 | 62.2% | View Chart |
P/BV | x | 4.8 | 4.8 | 101.7% | View Chart |
Dividend Yield | % | 1.0 | 0.8 | 123.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-21 |
SUN PHARMA Mar-21 |
ALKEM LABORATORIES/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,150 | 654 | 481.9% | |
Low | Rs | 2,224 | 339 | 656.7% | |
Sales per share (Unadj.) | Rs | 741.4 | 139.6 | 531.0% | |
Earnings per share (Unadj.) | Rs | 135.3 | 9.5 | 1,420.9% | |
Cash flow per share (Unadj.) | Rs | 158.3 | 18.2 | 870.0% | |
Dividends per share (Unadj.) | Rs | 30.00 | 7.50 | 400.0% | |
Avg Dividend yield | % | 1.1 | 1.5 | 73.9% | |
Book value per share (Unadj.) | Rs | 616.8 | 193.6 | 318.5% | |
Shares outstanding (eoy) | m | 119.57 | 2,399.34 | 5.0% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 3.6 | 102.0% | |
Avg P/E ratio | x | 19.9 | 52.1 | 38.1% | |
P/CF ratio (eoy) | x | 17.0 | 27.3 | 62.2% | |
Price / Book Value ratio | x | 4.4 | 2.6 | 170.0% | |
Dividend payout | % | 22.2 | 78.8 | 28.2% | |
Avg Mkt Cap | Rs m | 321,244 | 1,190,430 | 27.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 16,210 | 68,622 | 23.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 88,650 | 334,981 | 26.5% | |
Other income | Rs m | 2,332 | 8,592 | 27.1% | |
Total revenues | Rs m | 90,982 | 343,573 | 26.5% | |
Gross profit | Rs m | 19,424 | 41,616 | 46.7% | |
Depreciation | Rs m | 2,746 | 20,800 | 13.2% | |
Interest | Rs m | 589 | 1,414 | 41.7% | |
Profit before tax | Rs m | 18,421 | 27,994 | 65.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,243 | 5,147 | 43.6% | |
Profit after tax | Rs m | 16,178 | 22,847 | 70.8% | |
Gross profit margin | % | 21.9 | 12.4 | 176.4% | |
Effective tax rate | % | 12.2 | 18.4 | 66.2% | |
Net profit margin | % | 18.2 | 6.8 | 267.6% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 69,288 | 304,421 | 22.8% | |
Current liabilities | Rs m | 36,041 | 161,456 | 22.3% | |
Net working cap to sales | % | 37.5 | 42.7 | 87.9% | |
Current ratio | x | 1.9 | 1.9 | 102.0% | |
Inventory Days | Days | 20 | 149 | 13.1% | |
Debtors Days | Days | 66 | 99 | 67.0% | |
Net fixed assets | Rs m | 34,825 | 336,682 | 10.3% | |
Share capital | Rs m | 239 | 2,399 | 10.0% | |
"Free" reserves | Rs m | 73,517 | 462,229 | 15.9% | |
Net worth | Rs m | 73,756 | 464,628 | 15.9% | |
Long term debt | Rs m | 343 | 8,981 | 3.8% | |
Total assets | Rs m | 104,114 | 641,103 | 16.2% | |
Interest coverage | x | 32.3 | 20.8 | 155.2% | |
Debt to equity ratio | x | 0 | 0 | 24.0% | |
Sales to assets ratio | x | 0.9 | 0.5 | 163.0% | |
Return on assets | % | 16.1 | 3.8 | 425.6% | |
Return on equity | % | 21.9 | 4.9 | 446.1% | |
Return on capital | % | 25.7 | 6.2 | 413.2% | |
Exports to sales | % | 22.1 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 19,555 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 19,555 | 84,493 | 23.1% | |
Fx outflow | Rs m | 2,467 | 30,334 | 8.1% | |
Net fx | Rs m | 17,088 | 54,159 | 31.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 12,649 | 61,704 | 20.5% | |
From Investments | Rs m | -9,985 | 5,362 | -186.2% | |
From Financial Activity | Rs m | -2,718 | -59,805 | 4.5% | |
Net Cashflow | Rs m | -17 | 5,964 | -0.3% |
Indian Promoters | % | 57.1 | 54.5 | 104.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 19.6 | 34.5 | 56.7% | |
FIIs | % | 5.4 | 14.4 | 37.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 42.9 | 45.5 | 94.2% | |
Shareholders | 81,869 | 662,384 | 12.4% | ||
Pledged promoter(s) holding | % | 0.0 | 5.6 | - |
Compare ALKEM LABORATORIES With: CIPLA LUPIN DR. REDDYS LAB ZYDUS LIFESCIENCES AUROBINDO PHARMA
After opening on a positive note, Indian share markets failed to keep up early gains and ended the day marginally lower.
In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
Here's a rundown on Sun Pharma's June quarter results.
In the past three months, the stock has outperformed the market by gaining nearly 20%. Can it go higher?
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
As the new variant of Covid-19 emerges, keep an eye on these stocks.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More